GLP-1 week one check-ins: what the science says vs. the hype

What did @deja.strong actually say?

In a 19.8K-view TikTok check-in, @deja.strong reported finishing her first week on what she called "a Zimpik" (almost certainly Zepbound or Ozempic, given the GLP-1 hashtag) with three side effects: fatigue, dizziness, and nausea. She said the dizziness and nausea "only work for the first two days of the shot" while fatigue followed her all week, requiring daily naps. She also reported not losing two pounds and moving her body five times. She then announced starting the 75 Hard program in week two.

One quick note: "Zimpik" doesn't match any brand name on the market. Given her hashtags referencing the GLP-1 community and type 2 diabetes, she's almost certainly on semaglutide or tirzepatide. This matters because the two drugs have meaningfully different side effect profiles, and it's worth knowing which one you're actually on.

Does the science back this up?

Largely yes, with some nuance. The side effect timeline she describes is consistent with published trial data, though fatigue is underreported in the clinical literature compared to nausea.

The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) on tirzepatide found that gastrointestinal side effects, including nausea, were most common in the first few days after each injection and typically resolved before the next dose. The STEP 1 trial (Wilding et al., 2021, NEJM) on semaglutide found similar patterns. What's less documented in the headlines is fatigue. A 2023 post-marketing analysis published in Drug Safety (Raschi et al.) found fatigue appearing in real-world GLP-1 adverse event reports more frequently than trial data suggested, which tracks with what @deja.strong describes.

The dizziness is also consistent. Early-week injection dizziness can stem from mild dehydration or reduced caloric intake, both common in week one. It's not dangerous for most people but it's real.

What did they get wrong (or right)?

She got the side effect timeline mostly right. Short-lived nausea and dizziness peaking in the first 48 hours post-injection is well-supported. Credit where it's due.

The weight claim is where things get murky. She said she "didn't lose two pounds" in week one, which reads as slightly disappointed. But expecting two pounds in week one of a starting dose is unrealistic. GLP-1 medications typically begin at sub-therapeutic doses to reduce GI side effects, not to drive weight loss. The weight loss effect builds over weeks to months as the dose titrates upward. Expecting early dramatic results is a common misunderstanding and one that leads people to quit early. The STEP and SURMOUNT trials measured outcomes over 68 to 72 weeks, not seven days.

The 75 Hard combination is where a clinical flag belongs. 75 Hard requires two 45-minute workouts per day with zero rest days. In week two of a GLP-1 start, when appetite suppression and fatigue are already present, doubling exercise load without adequate caloric intake is a real risk. This isn't fearmongering. It's basic physiology. No one should be stacking aggressive exercise programs onto GLP-1 initiation without talking to their prescriber first.

What should you actually know?

Three things worth keeping in mind if you're in week one of a GLP-1 medication.

• Side effects are front-loaded by design. Starting doses are intentionally low. Nausea and dizziness in days one through three are expected and typically self-limiting. If they persist or worsen, that's a call to your provider, not a reason to tough it out.
• Week-one weight changes mean almost nothing. Early loss is often water weight. Early stalls are often the body adjusting. The clinical data on GLP-1 efficacy measures outcomes over months, not days. Managing expectations here is not pessimism. It's accuracy.
• Fatigue is real and underacknowledged. The trials didn't fully capture it, but post-market reports and patient communities consistently report it. Reduce activity intensity in the first week, not increase it. Adding 75 Hard in week two of GLP-1 initiation, particularly with a history of breast cancer treatment and PCOS-related metabolic factors, warrants a direct conversation with a physician before proceeding.

@deja.strong is sharing her genuine experience and that has real value for a community that often feels dismissed. But the 75 Hard escalation, on top of a medication start with documented fatigue effects, is the part of this video that needs a second look.